Sanofi US
NEWS
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
Sanofi said that the phase II/III trial studying venglustat in autosomal dominant polycystic kidney disease was scrapped because it “did not meet futility criteria.”
A two-stage Phase III clinical trial by Sanofi and GSK, is studying a COVID-19 vaccine candidate targeting the original SARS-CoV-2 strain as well as the South African B.1.351 variant.
Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
The high court’s decision will prevent Sandoz from launching its biosimilar to Amgen’s blockbuster rheumatoid arthritis drug.
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
JOBS
IN THE PRESS